| Literature DB >> 32397163 |
Geir Hetland1,2, Jon-Magnus Tangen3, Faiza Mahmood4, Mohammad Reza Mirlashari1, Lise Sofie Haug Nissen-Meyer1, Ivo Nentwich1, Stig Palm Therkelsen5, Geir Erland Tjønnfjord2,6,7, Egil Johnson2,8.
Abstract
Since the 1980s, medicinal effects have been documented in scientific studies with the related Basidiomycota mushrooms Agaricus blazei Murill (AbM), Hericium erinaceus (HE) and Grifola frondosa (GF) from Brazilian and Eastern traditional medicine. Special focus has been on their antitumor effects, but the mushrooms' anti-inflammatory and antiallergic properties have also been investigated. The antitumor mechanisms were either direct tumor attack, e.g., apoptosis and metastatic suppression, or indirect defense, e.g., inhibited tumor neovascularization and T helper cell (Th) 1 immune response. The anti-inflammatory mechanisms were a reduction in proinflammatory cytokines, oxidative stress and changed gut microbiota, and the antiallergic mechanism was amelioration of a skewed Th1/Th2 balance. Since a predominant Th2 milieu is also found in cancer, which quite often is caused by a local chronic inflammation, the three conditions-tumor, inflammation and allergy-seem to be linked. Further mechanisms for HE were increased nerve and beneficial gut microbiota growth, and oxidative stress regulation. The medicinal mushrooms AbM, HE and GF appear to be safe, and can, in fact, increase longevity in animal models, possibly due to reduced tumorigenesis and oxidation. This article reviews preclinical and clinical findings with these mushrooms and the mechanisms behind them.Entities:
Keywords: Agaricus blazei; Grifola frondosa; Hericium erinaceus; anti-inflammatory; antiallergic; antitumor; clinical studies; mushrooms
Mesh:
Substances:
Year: 2020 PMID: 32397163 PMCID: PMC7285126 DOI: 10.3390/nu12051339
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Antitumor effects of Agaricus blazei Murill—Preclinical studies.
| Product Admin. | Study In, Of | Effects | Mechanism | Author, Year [Ref] |
|---|---|---|---|---|
| Solid-state fermented mycelia, p.o. | Mice, Sarcoma | Growth inhibition | Immunomodulation | Rubel et al., 2018 [ |
| Ergosterol deriv. (Agarol), i.p. | SCID Mice, Lung Adenoarcinoma | Inhibition | Apoptosis | Shimizu et al., 2016 [ |
| Water mycelia extract incl. HE, GF, p.o. (Andosan) | Min Mice, spon. Adenocarcinoma | Inhibition | Immunomodulation, Apoptosis | Hetland et al., 2016 [ |
| Water mycelia extract, p.o. | Mice, Sarcoma | Antitumor | Immunoprotection | Bertéli et al., 2016 [ |
| Water extract + Chitosan, p.o. | SCID Mice, Hepatoma | Inhibition | Angiogenetic effect | Yeh et al., 2015 [ |
| Water extract, p.o. | Mice, Murine Leukemia | ↓ Liver & spleen size ↑ IL-1β,IL-6, IFNγ, ↓ IL-4 | ↑ T% B cells, ↓ MΦ Immunomodulation | Lin et al., 2012 [ |
| Water extract, p.o. | SCID Mice, colon cancer, Hepatoma Melanoma | Inhibition, Inhibition, ↑ Life span | Dose-dependent Immunomodulation | Wu et al., 2011 [ |
| β-glucan-rich extract, i.t. | Mice, Ehrlich, tumor | Inhibition, ↑ IFNγ, T cc, MΦ, ↓ IL-10 | Immune cell tumor migration Cytokine switch, Apoptosis | Pinto et al., 2009 [ |
| Crude fruiting body, p.o. | Rats, colon ca. | No effect on colon carcinogenesis | - | Ziliotto et al., 2009 [ |
| LMW polysacc., i.t., i.p. | Mice, Sarcoma Melanoma | Inhibition ↓ Lung metastasis | Inhib. Angiogenesis | Niu et al., 2009 [ |
| Broth fraction, p.o. | SCID mice, Prostate ca. | Inhibition | Apoptosis, Antiangiogenesis | Yu et al., 2009 [ |
| Water extract + marine phospholipid, p.o. | Nude Mice, Myeloma | Inhibition | Immunomodulation ↑ uptake of extract | Murakawa et al., 2007 [ |
| Ergosterol, p.o. | Mice, Sarcoma | Inhibition | ↓ Neo-vascularization | Takaku et al., 2001 [ |
| Water extract, p.o. | Mice, CP-induced clastogenicity | Anticarcinogenic | Antimutagenic | Delmanto et al., 2001 [ |
| Mycelia polysaccprotein complex, i.p., p.o. | Mice, Sarcoma | Inhibition | Immunological | Ito et al., 1997 [ |
Abbreviations: Severe combined immunodeficiency (SCID), intraperitoneally (i.p.), perorally (p.o.), intratumor (i.t.), interleukin (IL), interferon (IFN), macrophages (MΦ), cancer (ca.), cells (cc), low molecular weight (LMW), cyclophosphamide (CP).
Antitumor effects of Agaricus blazei Murill–Clinical studies.
| Product Admin. | Study In, Of | Effects | Mechanism | Author, Year [Ref] |
|---|---|---|---|---|
| Water mycelia extract incl. HE, GF, p.o. (Andosan) | Placebo-ctr RCT Myeloma pat. ( | Immunomodula-ting | Immunomodulation | Tangen et al., 2015 [ |
| Water extract, p.o. (Senseiro) | Prostate ca. patients ( | Longer PSA doubling time, no testosterone correlation | - | Yoshimura et al., 2010 [ |
| Water mycelia extract incl. HE, GF, p.o. (Andosan) | Patient with chron. HCV infection ( | ↑ Expression of “antitumor” genes | Immunomodulation | Grinde et al., 2006 [ |
| Water extract, p.o. | Gynecol. ca. patients ( | ↑ QoL, ↑ NK cc activ. | Immunomodulation | Ahn et al., 2004 [ |
| Water extract, p.o. | Ac. non-lymphoblastic leukemic patients ( | Inhibition | - | Hui et al., 1994 [ |
Abbreviations: Hericium erinaceus (HE), Grifola frondosa (GF), controls (ctr), randomized clinical trial (RCT), patients (pat.), prostate specific antigen (PSA), hepatitis C virus (HSV), quality of life (QoL), natural killer (NK).
Figure 1Follow-up of overall survival (OS) of patients included in the clinical study: AndosanTM as adjuvant treatment in MM patients receiving autologous stem cell transplantation (ASCT) [56]. Upper curve: AndosanTM group (n = 19). Median OS = 79.0 months (95% CI 61.5–96.5 months). Lower curve: Placebo group (n = 21). Median OS = 65.8 months (95% CI 50.5–80.9 months) Median observation time 67.7 months. p = 0.16. Previously unpublished result.
Antitumor effect of Grifola fondosa (Human study).
| Product, Admin. | Study In, Of | Effects | Mechanism | Author, Year [Ref] |
|---|---|---|---|---|
| GF β-glucan, p.o. | Mice, Heps tumor (hepatoma) | ↑ Inhibitory effect of 5-Fu against Heps-tumor | Synergism and immune regulation | Mao et al., 2019 [ |
| Selenium-enriched GF polysaccharide, p.o. | Mice, Heps tumor (hepatoma) | Inhibition of Heps-tumor | Improved immune function | Mao et al., 2018 [ |
| GF β-glucan, p.o. | Mice, Colon tumor, Melanoma | Inhibition, Systemic antitumor response | MΦ activ. in Peyer’s patches and ↑ IFNγ | Masuda et al., 2017 [ |
| GF mycelia extract, p.o. | Rats, Kidney ca. | Inhibition | Immunomodulation and tumor necrosis | Vetchinkina et al., 2016 [ |
| GF LMW protein fraction, i.p. | Mice, Colon ca. | Inhibition | ↑ IL-1, TNFα, IL-10, IL-12, IFNγ, activ. NK and DC cc, MΦ | Kodama et al., 2010 [ |
| GF polysacc., i.p. | Mice, Colon ca. | Inhibition | Induced cell mediated immunity ↑ Th1 cytokines | Masuda et al., 2009 [ |
| GF polysacc., i.p. | Mice, Colon ca. | ↑ Antitumor and-metastatic effect on cisplatin, ↓myelo- and nephrotoxicity | Synergistic effect of cisplatin cytotoxicity and GF immunomodulation | Masuda et al., 2009 [ |
| GF D fraction, p.o. | Diff. Cancer pat. ( | Hindered metastat. prog. ↓expression of tumor markers | Immunomodulation ↑NK cell activ. and ↑Th 1/↓Th2 | Kodama et al., 2003 [ |
| GF β-glucan, i.p. | Mice, Colon ca. | Inhibition | Induced cellular mediated immunity and Th1 dominance | Kodama et al., 2002 [ |
| GF β-glucan, i.p. | Mice, Sarcoma, Carcinoma | Inhibition | Host-mediated mechanism involving MΦ and cytotoxic T cc | Takeyama et al., 1987 [ |
| GF polysacc. fraction, i.p., i.t. | Mice, Sarcoma | Repression | ↑ Weight of spleen cc and number | Suzuki et al., 1985 [ |
Abbreviations: hepatocellular carcinoma (Heps), 5-Fluorouracil (5-Fu).
Anti-inflammatory effect of Agaricus blazei Murill, Hericium erinaceus and Grifola frondosa-Preclinical studies.
| Product, Admin. | Study In, Of | Effects | Mechanism | Author, Year [Ref] |
|---|---|---|---|---|
| AbM dry feed, p.o. | Mice, non-alcoholic steato-hepatitis | Prevention | Prevention of oxidative stress | Nakamura et al., 2019 [ |
| AbM water extract fractions | Mice, cerebral malaria | Improved consequence of cerebral malaria | ↓ TNFα, IL-6, IL-1β Antimalarial activity | Val et al., 2015 [ |
| AbM extract, p.o. | Rats, Pulmonary inflammation | ↓ Lung damage induced by carcinogen | Attenuation of pulmonary inflammation & gross consolidation | Croccia et al., 2013 [ |
| Erinacine A-enriched HE mycelia, p.o. | Mice, Life-prolonging activity | Increased longevity in aged mice | Induction of endogenous antioxidant enzymes | Li et al., 2019 [ |
| HE Polysaccharide, p.o. | Mice, Colitis | Attenuation of colitis, reversing of gut dysbiosis | Downregulation of oxidative stress and inflamm.-related signaling pathways, Maintaining intestinal barrier | Ren et al., 2018 [ |
| HE alcohol extract & polysacc., p.o. | Rats, IBD | Improved damages in colonic mucosa of induced IBD | ↓ MPO activ., NFKB, TNFα, ↑T cc activ. Beneficial gut bacteria growth and improved host immunity | Diling et al., 2017 [ |
| HE mycelium alcohol extract & erinacine A, p.o. | Rats, brain ischemia | Protection against brain ischemia injury induced neuronal cell death | Inhibition of iNOS/P3 MAPK, ↓ IL-1β, IL-6, TNFα, ↑ nerve growth properties | Lee et al., 2014 [ |
| GF polysacc., p.o. | Rats, non-alcoholic steato-hepatitis | Protection | Beneficial regulation of microbiota | Li et al., 2019 [ |
| Fermented GF extract, p.o. | Rats ET-induced uveitis | Anti-inflammatory | ↓ IL-1β, TNFα, NFΚB activ., iNOS express. | Han et al.., 2012 [ |
| GF water extract, p.o. | Rats, IBD | ↓ Colon ulceration | Amelioration by ↓MPO, TNFα colon express. and NFΚB signaling | Lee et al., 2010 [ |
Abbreviations: tumor necrosis factor (TNF), inflammatory bowel disease (IBD), myeloperoxidase (MPO), nuclear factor kappa B (NFKB), inducible nitric oxide synthase (iNOS), mitogen-activated protein kinase (MAPK), endotoxin (ET).
Anti-inflammatory effect of Agaricus blazei Murill—Clinical studies.
| Product, Admin. | Study In, Of | Effects | Mechanism | Author, Year [Ref] |
|---|---|---|---|---|
| AbM mycelia water extract incl. HE, GF, p.o. (Andosan) | Placebo-ctr RCT, IBD patients; 50 UC, 50 CD | Improved symptoms & QoL espec. in UC | ↓ Proinflammatory effect | Therkelsen et al., 2016 [ |
| AbM mycelia water extract incl. HE, GF, p.o. (Andosan) | Pilot study, IBD patients; 10 UC, 11 CD | Anti-inflammatory | ↓ Proinflammatory cytokines, ↓ fecal calprotectin | Førland et al., 2011 [ |
| AbM mycelia water extract incl. HE, GF, p.o. (Andosan) | Healthy Volunteers ( | Antioxidant effect | ↓iROS prod. and Adhesion molec. express. in MΦ and granuloc. | Johnson et al., 2012 [ |
| AbM mycelia water extract incl. HE, GF, p.o. (Andosan) | Healthy Volunteers ( | Predominantly anti-inflammatory effect | ↓Proinflammatory cytokines | Johnson et al., 2009 [ |
Abbreviations: ulcerative colitis (UC), Crohn’s disease (CD), intracellular reactive oxygen species (iROS).
Anti-allergic Effects of Agaricus blazei Murill and Grifola frondosa (Human study).
| Product, Admin. | Study In, Of | Effects | Mechanism | Author, Year, [Ref.] |
|---|---|---|---|---|
| AbM mycelia water extract incl. HE, GF, p.o. (Andosan) | Placebo-ctr RCT in blood donors, Pollen allergy & asthma ( | ↓ General symptoms, and medication | ↓ Spec. IgE, reduced basophil sensitivity | Mahmood et al., 2019 [ |
| Water AbM extract, p.o. | Mice, Allergy | ↓ OVA sensitization | ↓ Spec. IgE, improv. Th1/Th2 balance via MΦ activ. by epithelial cc, diff. promotion of naïve T cc to Th1 cc | Bouike et al., 2011 [ |
| AbM mycelia water extract incl. HE, GF, p.o. (Andosan) | Mice, Allergy | ↓ OVA sensitization | ↓ Spec. IgE, IgG1 and improved Th1/Th2 balance | Ellertsen & Hetland 2009 [ |
| AbM water extract, p.o. | Mice, Asthma | ↓ Spec. IgE, IgG1 and bronchial eosinophils | Amelioration of skewed Th1/Th2 balance | Takimoto et al., 2008 [ |
| AbM water extract, p.o. | Mice, Anaphylaxis | Inhib. of induced anaphylactic reaction and ear swelling | Treatment of mast cell mediated anaphylactic reaction | Choi et al., 2006 [ |
| GF alcohol extract and ergosterol, p.o. | Mice, Allergic inflammation | Inhib. mast cc degranulation, alleviated anaphylactic cutaneous response | ↓ Type 1 allergic reaction by suppression of mast cc degranulation | Kawai et al., 2019 [ |
| GF polysacch, p.o. | Mice, AD | Inhib. AD-like skin lesion | ↓ IgE, mast cc infiltr., cytokine express. controlling Th1/Th2 | Park et al., 2015 [ |
Abbreviations: immunoglobulin (Ig), ovalbumin (OVA), atopic dermatitis (AD).
Safety of Agaricus blazei Murill, Grifola frondosa and Hericium erinaceus (Human Studies).
| Product Admin. | Study In, Of | Effects | Mechanism | Author, Year [Ref] |
|---|---|---|---|---|
| AbM powder, p.o. | Rats, Toxicity and oncogenicity | ↓ Mortality in 2-yrs toxicity study | Possible anti-mutagenic and antioxidant effect, No carcinogenicity | Lee et al., 2008 [ |
| AbM water extract, p.o. | Rats, Subchronic toxicity | Low subchronic toxicity at very high doses | Neg. genotoxicity test, possible clastogenic activity but no direct effect on DNA | Sumiya et al., 2008 [ |
| AbM water extract, p.o. | Human case ( | Allergic chron. cheilitis, pos. delayed reaction after patch testing | Daily AbM intake for 6 months | Suehiro et al., 2007 [ |
| AbM extract, p.o. | Cancer patients ( | Severe hepatic dysfunction | - | Mukai et al., 2006 [ |
| GF polysacc., p.o. | Phase I/II safety study in 34 breast ca. pat. | No dose-limiting toxicity | - | Deng et al., 2009 [ |
| GF spore, inhalation | Human case ( | Occupational hypersensitivity pneumonitis | Work for 3 mo. in mushroom farm | Tanaka et al., 2004 [ |
| Erinacine A-enriched HE mycelia, p.o. | Mice, Life-prolonging activity | Increased longevity in aged mice | Induction of endogenous antioxidant enzymes | Li et al., 2019 [ |